JP5046922B2 - 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 - Google Patents
少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 Download PDFInfo
- Publication number
- JP5046922B2 JP5046922B2 JP2007510074A JP2007510074A JP5046922B2 JP 5046922 B2 JP5046922 B2 JP 5046922B2 JP 2007510074 A JP2007510074 A JP 2007510074A JP 2007510074 A JP2007510074 A JP 2007510074A JP 5046922 B2 JP5046922 B2 JP 5046922B2
- Authority
- JP
- Japan
- Prior art keywords
- fludarabine
- treatment
- derivative
- pbd
- pbd derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
(式中、式に示された点線はそれら点線が結合する原子の間の第二の随意に存在しうる(optional)結合手を表わし、そしてXが結合する炭素原子とRが結合する窒素原子との間に第二の結合手が存在する場合にはRは存在せずかつXは水素を表わし、あるいはXが結合する炭素原子とRが結合する窒素原子との間に第二の結合手が存在しない場合にはRは水素を表わしかつXは−OHを表わし、
そして
X1が結合する炭素原子とR1が結合する窒素原子との間に第二の結合手が存在する場合にはR1は存在せずかつX1は水素を表わし、あるいはX1が結合する炭素原子とR1が結合する窒素原子との間に第二の結合手が存在しない場合にはR1は水素を表わしかつX1は−OHを表わすものとする)の化合物;
又はかかる化合物の酸付加塩及び/又は溶媒和物及び/又は水和物であって、それらは非晶質又は結晶質体、ラセミ体又は光学活性体又はこれらの型のすべての組み合わせで存在することができ;
及び(又は)生理学的条件下で、前記定義したごとき化合物のいずれかを生成し得る任意の化合物;
及び(又は)前記列挙した化合物のいくつか又はそれら化合物のすべての任意の混合物;
をも包含する。
の化合物;
及び(又は)水又はアルコールの添加によって形成されるモノ−及び/又はビス−カルビノール;
及び(又は)かかる化合物の酸付加塩及び/又は溶媒和物及び/又は水和物;
及び(又は)かかる化合物の酸付加塩及び/又は溶媒和物及び/又は水和物;それらが非晶質又は結晶質体、ラセミ体又は光学活性体の形態で存在する化合物;
及び(又は)生理学的条件下で、前記定義したごとき化合物のいずれかを生成し得る任意の化合物;
及び(又は)前記列挙した化合物のいくつか又はそれら化合物のすべての任意の混合物を指す。
上記した本発明の手順を例証するために以下に実験例を示すが、これらが本発明の範囲を限定すると考えるべきものでないことは勿論である。
フルダラビン: 1.10−7M−1.10−5M
PBD誘導体: 1.10−11M−1.10−7M
各治療剤について適切な投与用量範囲を確定する目的で、投与用量―応答曲線(dose-response curves)を作成し、そしてLD50値をS字型(sigmoidal)非線形回帰分析法を使用することによって計算した。
──────────────────────────────────────
モル比: 1/100 1/250 1/500
──────────────────────────────────────
CI値: 0.41 0.93 1.42
──────────────────────────────────────
該実験にそれぞれ単用された化合物(PBD誘導体及びフルダラビン)について、または両者化合物を組み合わせて1/100、1/250及び1/500の既定のモル比で併用した時のこれら2つの化合物についてのそれぞれの場合の投与用量―応答曲線を、それぞれ図1−図3に示す。図1−図3において、faは有効な効果のあった部分(fraction)〔細胞アポトーシス(apoptosis)の生起〕を示し、fuは有効な効果を受けなかった部分(fraction)〔すなわち細胞の生存持続(viable)〕を示し、logDは化合物または製剤の濃度の対数を表わす。
Claims (17)
- 血液病の治療のための請求項1に記載の使用。
- 白血病の治療のための前記請求項1〜2のいずれかに記載の使用。
- 慢性リンパ性白血病の治療のための請求項3に記載の使用。
- PBD誘導体を1.10−11Mと1.10−7Mとの間の範囲の濃度で使用することを特徴とする前記請求項1〜4のいずれかに記載の使用。
- フルダラビンを1.10−7Mと1.10−5Mとの間の範囲の濃度で使用することを特徴とする前記請求項1〜4のいずれかに記載の使用。
- PBD誘導体/フルダラビンのモル比が1/100であることを特徴とする前記請求項1〜6のいずれかに記載の使用。
- 癌治療の目的用に、請求項1記載の式(II)のPBD誘導体とフルダラビンとを同時に、又は持続的に使用、投与するために用いられる、薬物併用製剤としての、PBD誘導体とフルダラビンとを含んでなる製剤。
- 同時使用のために用いられる、薬物併用製剤としての請求項8に記載の製剤。
- 持続的に使用するために用いられる、薬物併用製剤としての請求項8に記載の製剤。
- 血液病の治療のための請求項8ないし10のいずれかに記載の製剤。
- 白血病の治療のための請求項8ないし11のいずれかに記載の製剤。
- 慢性リンパ性白血病の治療のための請求項12に記載の製剤。
- PBD誘導体を1.10−11Mと1.10−7Mとの間の範囲の濃度で使用することを特徴とする請求項8ないし13のいずれかに記載の製剤。
- フルダラビンを1.10−7Mと1.10−5Mとの間の範囲の濃度で使用することを特徴とする請求項8ないし14のいずれかに記載の製剤。
- PBD誘導体/フルダラビンのモル比が1/250であることを特徴とする請求項8ないし15のいずれかに記載の製剤。
- PBD誘導体/フルダラビンのモル比が1/100であることを特徴とする請求項8ないし15のいずれかに記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0404424 | 2004-04-27 | ||
FR0404424A FR2869231B1 (fr) | 2004-04-27 | 2004-04-27 | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
PCT/FR2005/001025 WO2005105113A2 (fr) | 2004-04-27 | 2005-04-26 | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007534730A JP2007534730A (ja) | 2007-11-29 |
JP5046922B2 true JP5046922B2 (ja) | 2012-10-10 |
Family
ID=34947843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007510074A Expired - Fee Related JP5046922B2 (ja) | 2004-04-27 | 2005-04-26 | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8034808B2 (ja) |
EP (1) | EP1742644B1 (ja) |
JP (1) | JP5046922B2 (ja) |
AT (1) | ATE538801T1 (ja) |
CA (1) | CA2564603C (ja) |
CY (1) | CY1112387T1 (ja) |
DK (1) | DK1742644T3 (ja) |
ES (1) | ES2377066T3 (ja) |
FR (1) | FR2869231B1 (ja) |
NO (1) | NO338380B1 (ja) |
PL (1) | PL1742644T3 (ja) |
PT (1) | PT1742644E (ja) |
SI (1) | SI1742644T1 (ja) |
WO (1) | WO2005105113A2 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
GB0410725D0 (en) * | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
DE102008050988A1 (de) * | 2008-09-01 | 2010-03-04 | Gerd Reime | Identifikationselement mit einem optischen Transponder |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
CN102971329B (zh) | 2010-04-15 | 2016-06-29 | 麦迪穆有限责任公司 | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
AU2012311505B2 (en) | 2011-09-20 | 2016-09-29 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
MX341523B (es) | 2011-10-14 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas. |
CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
CN110183470A (zh) | 2011-10-14 | 2019-08-30 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
CN104334580B (zh) | 2012-02-24 | 2018-03-30 | 艾伯维施特姆森特克斯有限责任公司 | 抗sez6抗体及使用方法 |
AU2013328674B2 (en) | 2012-10-12 | 2017-06-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
TR201815418T4 (tr) | 2012-10-12 | 2018-11-21 | Adc Therapeutics Sa | Pirrolobenzodiazepin -anti-psma antikor konjugatları. |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
HUE042731T2 (hu) | 2012-10-12 | 2019-07-29 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
EP2906296B1 (en) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
EP2906251B1 (en) | 2012-10-12 | 2017-09-27 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
RS58873B1 (sr) | 2013-02-22 | 2019-08-30 | Abbvie Stemcentrx Llc | Antidll3-antitelo-pbd konjugati i njihova upotreba |
US9821074B2 (en) | 2013-03-13 | 2017-11-21 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
ES2871418T3 (es) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Composiciones y métodos de conjugación de anticuerpos específicos de sitio |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
KR20160070191A (ko) | 2013-11-06 | 2016-06-17 | 스템센트알엑스 인코포레이티드 | 신규한 항-클라우딘 항체 및 사용 방법 |
AU2014361856A1 (en) | 2013-12-12 | 2016-06-30 | Abbvie Stemcentrx Llc | Novel anti-DPEP3 antibodies and methods of use |
AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
EP3122757B1 (en) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
ES2830385T3 (es) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anticuerpos e inmunoconjugados anti-HER2 |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP2019522960A (ja) | 2016-04-21 | 2019-08-22 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗bmpr1b抗体及び使用方法 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
JP7138350B2 (ja) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法 |
LT3544636T (lt) | 2017-02-08 | 2021-06-25 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
EP3612537B1 (en) | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
MX2020001880A (es) | 2017-08-18 | 2021-07-06 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina. |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188378A (en) * | 1978-01-04 | 1980-02-12 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine |
DE69930328T2 (de) * | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
JP2004518615A (ja) * | 2000-08-09 | 2004-06-24 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 癌の処置に有用なインドール化合物 |
CA2474805A1 (en) * | 2002-02-28 | 2003-09-04 | Novartis Ag | Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents |
AU2004284075A1 (en) | 2003-10-22 | 2005-05-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
-
2004
- 2004-04-27 FR FR0404424A patent/FR2869231B1/fr not_active Expired - Fee Related
-
2005
- 2005-04-26 ES ES05762344T patent/ES2377066T3/es active Active
- 2005-04-26 US US11/587,962 patent/US8034808B2/en not_active Expired - Fee Related
- 2005-04-26 CA CA2564603A patent/CA2564603C/fr not_active Expired - Fee Related
- 2005-04-26 EP EP05762344A patent/EP1742644B1/fr active Active
- 2005-04-26 PL PL05762344T patent/PL1742644T3/pl unknown
- 2005-04-26 PT PT05762344T patent/PT1742644E/pt unknown
- 2005-04-26 WO PCT/FR2005/001025 patent/WO2005105113A2/fr active Application Filing
- 2005-04-26 AT AT05762344T patent/ATE538801T1/de active
- 2005-04-26 SI SI200531475T patent/SI1742644T1/sl unknown
- 2005-04-26 DK DK05762344.9T patent/DK1742644T3/da active
- 2005-04-26 JP JP2007510074A patent/JP5046922B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-21 NO NO20065368A patent/NO338380B1/no not_active IP Right Cessation
-
2012
- 2012-02-22 CY CY20121100181T patent/CY1112387T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007534730A (ja) | 2007-11-29 |
WO2005105113A2 (fr) | 2005-11-10 |
ES2377066T3 (es) | 2012-03-22 |
CA2564603C (fr) | 2014-07-29 |
CA2564603A1 (en) | 2005-11-10 |
PL1742644T3 (pl) | 2012-05-31 |
FR2869231B1 (fr) | 2008-03-14 |
WO2005105113A3 (fr) | 2007-02-22 |
FR2869231A1 (fr) | 2005-10-28 |
US8034808B2 (en) | 2011-10-11 |
NO338380B1 (no) | 2016-08-15 |
ATE538801T1 (de) | 2012-01-15 |
US20070232592A1 (en) | 2007-10-04 |
SI1742644T1 (sl) | 2012-03-30 |
NO20065368L (no) | 2006-11-21 |
PT1742644E (pt) | 2012-03-02 |
EP1742644B1 (fr) | 2011-12-28 |
DK1742644T3 (da) | 2012-04-16 |
EP1742644A2 (fr) | 2007-01-17 |
CY1112387T1 (el) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
AU2012321106B2 (en) | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent | |
KR20170012562A (ko) | 글루타미나제 억제제를 사용하는 병용 요법 | |
JP7047148B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ(cerdulatinib) | |
JP2010515709A5 (ja) | ||
KR20160078987A (ko) | 플리나불린 및 탁산의 조합에 의한 암 치료 | |
JP2024050668A (ja) | がんの治療方法 | |
US20170232017A1 (en) | Treatment of cancer | |
JP2021523189A (ja) | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
JP2023502742A (ja) | Alk2阻害剤及びjak2阻害剤を含む併用療法 | |
KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
EP3407887B1 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
TW201321383A (zh) | 用於預防及治療非小細胞肺癌之包含吡嗪并三嗪衍生物的組成物 | |
KR20050106119A (ko) | 항종양 효과 증강제 및 항종양제 | |
CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
KR20080034151A (ko) | 암 치료를 위한 조스퀴다르, 다우노루비신 및 시타라빈 | |
EP3010508B1 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
KR20190099500A (ko) | 암 치료용 약물 조성물 및 그 응용 | |
US20200397799A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
EA045240B1 (ru) | Способы лечения рака | |
JP6239745B2 (ja) | がんの処置のための、ro5503781及びカペシタビンの組み合わせ | |
JP2021063014A (ja) | 白血病治療薬 | |
WO2006124884A2 (en) | Dosing regimen | |
WO2011152515A1 (ja) | インドール化合物を含有する抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120516 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120620 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120717 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150727 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5046922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |